Next Article in Journal
Canonical, Non-Canonical and Atypical Pathways of Nuclear Factor кb Activation in Preeclampsia
Next Article in Special Issue
Hydroa Vacciniforme and Hydroa Vacciniforme-Like Lymphoproliferative Disorder: A Spectrum of Disease Phenotypes Associated with Ultraviolet Irradiation and Chronic Epstein–Barr Virus Infection
Previous Article in Journal
Consequences of Vitamin A Deficiency: Immunoglobulin Dysregulation, Squamous Cell Metaplasia, Infectious Disease, and Death
Review

Basal Cell Carcinoma: A Comprehensive Review

1
Division of Dermatology, Azienda Ospedaliero-Universitaria di Bologna, via Massarenti 9, 40138 Bologna, Italia
2
Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40138 Bologna, Italy
3
Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40138 Bologna, Italy
4
Laboratory of Bioengineering, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40138 Bologna, Italy
5
Dermatology Clinic, University of Rome Tor Vergata Rome, 00133 Rome, Italy
6
Ospedale Maggiore, 40133 Bologna, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(15), 5572; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21155572
Received: 16 June 2020 / Revised: 28 July 2020 / Accepted: 3 August 2020 / Published: 4 August 2020
Basal cell carcinoma (BCC) is the most common type of carcinoma worldwide. BCC development is the result of a complex interaction between environmental, phenotypic and genetic factors. However, despite the progress in the field, BCC biology and mechanisms of resistance against systemic treatments have been poorly investigated. The aim of the present review is to provide a revision of BCC histological and molecular features, including microRNA (miRNA) dysregulation, with a specific focus on the molecular basis of BCC systemic therapies. Papers from the last ten years regarding BCC genetic and phenotypic alterations, as well as the mechanism of resistance against hedgehog pathway inhibitors vismodegib and sonidegib were included. The involvement of miRNAs in BCC resistance to systemic therapies is emerging as a new field of knowledge. View Full-Text
Keywords: basal cell carcinoma; microRNA; genetic; treatment; hedgehog pathway inhibitors; vismodegib; sonidegib basal cell carcinoma; microRNA; genetic; treatment; hedgehog pathway inhibitors; vismodegib; sonidegib
Show Figures

Figure 1

MDPI and ACS Style

Dika, E.; Scarfì, F.; Ferracin, M.; Broseghini, E.; Marcelli, E.; Bortolani, B.; Campione, E.; Riefolo, M.; Ricci, C.; Lambertini, M. Basal Cell Carcinoma: A Comprehensive Review. Int. J. Mol. Sci. 2020, 21, 5572. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21155572

AMA Style

Dika E, Scarfì F, Ferracin M, Broseghini E, Marcelli E, Bortolani B, Campione E, Riefolo M, Ricci C, Lambertini M. Basal Cell Carcinoma: A Comprehensive Review. International Journal of Molecular Sciences. 2020; 21(15):5572. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21155572

Chicago/Turabian Style

Dika, Emi, Federica Scarfì, Manuela Ferracin, Elisabetta Broseghini, Emanuela Marcelli, Barbara Bortolani, Elena Campione, Mattia Riefolo, Costantino Ricci, and Martina Lambertini. 2020. "Basal Cell Carcinoma: A Comprehensive Review" International Journal of Molecular Sciences 21, no. 15: 5572. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21155572

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop